Compare GE Vernova Inc (GEV) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs GeneDx Holdings Corp — how do they compare? GE Vernova Inc trades at $1,003.06 (market cap $266.16B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: GE Vernova Inc is far larger — about 131.8× GeneDx Holdings Corp's market cap, and GE Vernova Inc pays a 0.2% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and GeneDx Holdings Corp for 19 Days on average.
| GEV | WGS | |
|---|---|---|
Market Cap | $266.16B | $2.02B |
Volume | 2,324,165 | 734,640 |
Sector | Industrials | Health |
52-Week High | $1.17K | $167.51 |
52-Week Low | $547.96 | $34.51 |
Typical Hold Time | 36 Days | 19 Days |
Enterprise Value | $255.83B | $2.05B |
Dividend Yield | 0.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $1,007.77, up 1.07% with strong bullish technical momentum. The stock shows impressive fundamental growth with 2026 revenue projected at $41.4B and net profit margin expanding to 23.03%. Recent catalysts include securing the first US construction permit for its BWRX-300 small modular reactor and a $176B backlog. Analyst consensus remains strongly bullish with 22 buy ratings and a $1,270 price target, representing 26% upside potential from current levels.
The outlook remains positive given the company's positioning in AI-driven power infrastructure demand, though valuation multiples appear elevated with P/E at 28.65 and EV/EBITDA at 85.22. Key risks include execution challenges in the wind segment and competitive pressures in the nuclear energy space. The stock's recent 45% YTD gain suggests much optimism is already priced in, requiring continued strong execution to justify further upside.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
